Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 159,607 |
|
|||||
| News | - | ||||||
| Day High | 2.20 | Low High |
|||||
| Day Low | 2.145 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adicet Bio Inc | ACET | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -1.82% | 2.16 | 16:49:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.145 | 2.145 | 2.20 | 2.19 | 2.20 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,734 | 159,607 | $ 2.18 | $ 347,950 | - | 1.10 - 7.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:49:01 | formt | 1,725 | $ 2.16 | USD |
Adicet Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 98.42M | 43.16M | - | 0 | -142.66M | -3.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adicet Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACET Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.20 | 2.31 | 2.13 | 2.22 | 534,527 | -0.04 | -1.82% |
| 1 Month | 1.97 | 2.43 | 1.9298 | 2.21 | 777,303 | 0.19 | 9.64% |
| 3 Months | 2.63 | 3.62 | 1.88 | 2.58 | 1,535,398 | -0.47 | -17.87% |
| 6 Months | 1.37 | 3.77 | 1.10 | 2.46 | 1,113,712 | 0.79 | 57.66% |
| 1 Year | 5.67 | 7.50 | 1.10 | 2.71 | 890,772 | -3.51 | -61.90% |
| 3 Years | 12.98 | 21.87 | 1.10 | 8.28 | 645,011 | -10.82 | -83.36% |
| 5 Years | 14.98 | 21.87 | 1.10 | 8.48 | 561,277 | -12.82 | -85.58% |
Adicet Bio Description
| Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |
